I used to work on Biogen’s Alzheimer’s drug. Is it spinning bad data?

I used to work on Biogen’s Alzheimer’s drug. Is it spinning bad data?

I used to work on Biogen’s Alzheimer’s drug. Is the company spinning bad data?

By TED WHITFORD

DOMINICK REUTER/AFP/GETTY IMAGES

When Biogen announced a second look at its futility analysis for aducanumab, I thought of CEO George Scanos announcing that dexpramipexole had failed.

READ MORE